9291 can be used for patients with lung cancer, especially if the pathology is adenocarcinoma and genetic sequencing shows EGFR mutation. If oral 9291 is resistant, the target drug can be replaced, and the most traditional ERSA is Gefitinib for treatment according to the genetic test results, and systemic intravenous chemotherapy can be chosen for patients with recurrent drug resistance, because adenocarcinoma can be treated with docetaxel, or pemetrexed if it is less effective, and if economic conditions allow, it can also be combined with The most common metastatic organs are the liver and the skull. Intravenous chemotherapy can also control the metastasis and growth of the tumor to a certain extent.